In vivo neuroimaging and behavioral correlates in a rat model of chemotherapy-induced cognitive dysfunction.

Adjuvant chemotherapy has been used for decades to treat cancer, and it is well known that disruptions in cognitive function and memory are common chemotherapeutic adverse effects. However, studies using neuropsychological metrics have also reported group differences in cognitive function and memory...

Descripción completa

Detalles Bibliográficos
Publicado en:Brain Imaging & Behavior Vol. 12; no. 1; pp. 87 - 96
Autores principales: Barry, Robert L., Byun, Nellie E., Tantawy, M. Noor, Mackey, Chase A., Wilson, George H., Stark, Adam J., Flom, Michael P., Gee, Laura C., Quarles, C. Chad, Wilson, George H 3rd
Formato: research Journal Article
Publicado: Springer Nature Feb2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128033929&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 128033929
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        19317557
        3GSC
      jtl: Brain Imaging & Behavior
      issn: 19317557
      maglogo: N
    pubinfo:
      dt: Feb2018
      vid: 12
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        128033929
        128033929
        NLM28108946
        128033929
        10.1007/s11682-017-9674-2
        NLM28108946
        128033929
      ppf: 87
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: In vivo neuroimaging and behavioral correlates in a rat model of chemotherapy-induced cognitive dysfunction.
      aug:
        au:
          Barry, Robert L.
          Byun, Nellie E.
          Tantawy, M. Noor
          Mackey, Chase A.
          Wilson, George H.
          Stark, Adam J.
          Flom, Michael P.
          Gee, Laura C.
          Quarles, C. Chad
          Wilson, George H 3rd
        affil: Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA
      sug:
        subj:
          Brain Drug Effects
          Antineoplastic Agents
          Doxorubicin
          Brain
          Models, Biological
          Animal Studies
          Magnetic Resonance Imaging
          Radiopharmaceuticals
          Female
          Tomography, Emission-Computed
          Tomography, X-Ray Computed
          Brain Mapping
          Rats
          Fludeoxyglucose F 18
          Conditioning (Psychology) Drug Effects
          Neuroradiography
          Recognition (Psychology) Drug Effects
          Fear Drug Effects
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Female
      ab: Adjuvant chemotherapy has been used for decades to treat cancer, and it is well known that disruptions in cognitive function and memory are common chemotherapeutic adverse effects. However, studies using neuropsychological metrics have also reported group differences in cognitive function and memory before or without chemotherapy, suggesting that complex factors obscure the true etiology of chemotherapy-induced cognitive dysfunction (CICD) in humans. Therefore, to better understand possible mechanisms of CICD, we explored the effects of CICD in rats through cognition testing using novel object recognition (NOR) and contextual fear conditioning (CFC), and through metabolic neuroimaging via [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET). Cancer-naïve, female Sprague-Dawley rats were administered either saline (1 mL/kg) or doxorubicin (DOX) (1 mg/kg in a volume of 1 mL/kg) weekly for five weeks (total dose = 5 mg/kg), and underwent cognition testing and PET imaging immediately following the treatment regime and 30 days post treatment. We did not observe significant differences with CFC testing post-treatment for either group. However, the chemotherapy group exhibited significantly decreased performance in the NOR test and decreased 18F-FDG uptake only in the prefrontal cortex 30 days post-treatment. These results suggest that long-term impairment within the prefrontal cortex is a plausible mechanism of CICD in this study, suggesting DOX-induced toxicity in the prefrontal cortex at the dose used.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N